HC
CORT icon

Hurley Capital’s Corcept Therapeutics CORT Stock Holding History

Hurley Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.7K Hold
100
– – ﹤0.01% 340
2026
Q1 		$4.03K Hold
100
– – ﹤0.01% 482
2025
Q4 		$3.48K Hold
100
– – ﹤0.01% 476
2025
Q3 		$8.31K Buy
+100
New +$7.24K ﹤0.01% 383

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hurley Capital's CORT Position: Q2 2026 in Review

Hurley Capital held its Corcept Therapeutics (CORT) position steady in Q2 2026 at 100 shares worth $8.7K. The position accounts for ﹤0.01% of the portfolio, ranked #340.

Hurley Capital first reported a position in CORT in Q3 2025 and has held it in 4 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Hurley Capital held 100 shares of Corcept Therapeutics worth $8.7K as of Q2 2026.
  • Hurley Capital left its Corcept Therapeutics share count unchanged in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Hurley Capital's portfolio in Q2 2026, its #340 holding.
  • Hurley Capital first reported a position in Corcept Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Hurley Capital's 13F filing for Q2 2026, filed 10 Aug 2026.